Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-01

Study Completion Date

2022-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Procalcitonin is a protein consisting of 116 amino-acids which can rapidly rise under inflammatory conditions and sepsis. More than 20 years ago it has been shown that dipeptidylpeptidase-4 (DPP-4) cleaves procalcitonin from the n-terminus, resulting in a truncated procalcitonin-variant which consists of 114 aminoacids. Within their workgroup the investigators found that the truncated procalcitonin-variant had deleterious effects on vascular integrity during sepsis in mice. However, it is unknown if this applies also in humans. By using an ELISA-assay the investigators want to examine the ratio between native and truncated human procalcitonin during diseases accompanied with hyperprocalcitoninemia and correlate the results with clinical data.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PredIcting SterOid DepeNdEnt LivEr InjuRy with Polyreactive Immunoglobulin G

NCT05810480

Autoimmune Hepatitis Autoimmune Liver Disease

RECRUITING

Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis

NCT03740685

Pancreatitis, Acute

UNKNOWN

Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis

NCT07010250

ANCA Associated Vasculitis Extramembranous Glomerulopathy Nephrotic Syndrome, Minimal Change +4 more

NOT_YET_RECRUITING

C-reactive Protein & Albumin Ratio IN AKI

NCT07335757

Acute Kidney Injuries

NOT_YET_RECRUITING

Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients: Impact of Ferretin and D -Dimer.

NCT06080750

Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Procalcitonin is a protein consisting of 116 amino-acids which can rapidly rise under inflammatory conditions and sepsis. More than 20 years ago it has been shown that dipeptidylpeptidase-4 (DPP-4) cleaves procalcitonin from the n-terminus, resulting in a truncated procalcitonin-variant which consists of 114 aminoacids.

Within their workgroup the investigators found that the truncated procalcitonin-variant had deleterious effects on vascular integrity during sepsis in mice: They observed that binding of truncated procalcitonin to the CRLR/RAMP1-receptor on vascular endothelium lead to phosphorylation and destruction of VE-cadherin, an essential part of adherens junctions. Consequently, paracellular leakage of proteins and fluid from blood vessels developed.

It is unknown if these effects also apply to humans. By using an ELISA-assay the investigators want to examine the ratio between native and truncated human procalcitonin during diseases accompanied with hyperprocalcitoninemia and correlate the results with clinical data. Futhermore, they want to examine if the procalcitonin-variants have influence on cytokine levels and surface antigens on immune cells by performing multiplex immunoassays and FACS-analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Pre-Eclampsia Granulomatosis With Polyangiitis Microscopic Polyangiitis Adiposity SIRS Procalcitonin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sepsis

Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.